The Swedish investment company Nordic Capital has taken over Maersk Medical, which among others production facilities in Singapore and Malaysia.
Maersk Medical is one of Denmark’s leading med-tech companies. Maersk Medical develops, produces and markets sterile single-use medical devices to the health care sector. The product portfolio includes disposable medical devices such as catheters, surgical aids, drainage bags, electrodes, wound care products and infusion devices. These products are primarily used in hospitals’ operating rooms and intensive care units, but also within the home care market and among general practitioners.
One of the product areas where Maersk Medical has experienced substantial growth in recent years is insulin infusion devices for diabetics using insulin pumps. Insulin pump therapy represents a steadily increasing share of the diabetes market and Maersk Medical is today the market leader in insulin infusion sets.
The company is also business partner for other med-tech companies looking to outsource parts of their production. In the coming years this area is expected to provide further growth for Maersk Medical.
Maersk Medical employs a total of 4,500 people world wide and is hadquartered in Lynge North of the Danish capital Copenhagen. It sells its products worldwide through sales companies in 12 countries including the USA, and through independent distributors in all other major markets. The turnover for last year is expected to reach DKK 1,9 milliarder.
Nordic Capital is a predominantly Swedish leading private equity investment firm in the Nordic region. Since its foundation in 1989, Nordic Capital has acquired 49 companies including add-on acquisitions, acting in all cases as the lead investor. The average turnover of the acquired companies has been SEK 1.5 billion.
Some of the the other companies owned by Nordic Capital are also active in South East Asia. Examples are M๖lnlycke with a factory in Thailand and Wilson Logistics with offices in several of the region’s capitals.
According to Bo S๖derberg of Nordic Capital the company will continue to strengthen and develop Maersk Medical’s profile as a successful and leading
manufacturer of single-use medical devices. The future focus will be on further strengthening innovation and product development as well as strengthening the company’s customer relations.
“In addition to increased organic growth, we will search for add-on acquisitions within certain chosen segments,” Mr. S๖derberg says.
The acqusition comes as a relief for the top management of Maersk Medical.
“We are happy that the future ownership of Maersk Medical now is determined,” says Remy Cramer, who remains CEO of Maersk Medical.
“Nordic Capital is known as a competent and responsible owner, and management and employees look forward to continuing the company’s positive development.”